These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23941761)

  • 1. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
    Seifert ME; de las Fuentes L; Rothstein M; Dietzen DJ; Bierhals AJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
    Am J Nephrol; 2013; 38(2):158-67. PubMed ID: 23941761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Fang Y; Ginsberg C; Seifert M; Agapova O; Sugatani T; Register TC; Freedman BI; Monier-Faugere MC; Malluche H; Hruska KA
    J Am Soc Nephrol; 2014 Aug; 25(8):1760-73. PubMed ID: 24578135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P; Prié D; Keddad K; Preston P; Wilde P; Wan H; Copley JB
    BMC Nephrol; 2014 May; 15():71. PubMed ID: 24885942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
    Andrews ES; Perrenoud L; Nowak KL; You Z; Pasch A; Chonchol M; Kendrick J; Jalal D
    PLoS One; 2018; 13(10):e0205831. PubMed ID: 30356327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA; Eelderink C; Hoekstra T; van Ballegooijen AJ; Raijmakers P; Beulens JW; de Borst MH; Vervloet MG
    Trials; 2022 Sep; 23(1):769. PubMed ID: 36096824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD.
    Levin A; Tang M; Perry T; Zalunardo N; Beaulieu M; Dubland JA; Zerr K; Djurdjev O
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1447-1460. PubMed ID: 28550081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
    Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
    J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
    Witham MD; Lees JS; White M; Band M; Bell S; Chantler DJ; Ford I; Fulton RL; Kennedy G; Littleford RC; McCrea IV; McGlynn D; Panarelli M; Ralston MR; Rutherford E; Severn A; Thomson N; Traynor JP; Struthers AD; Wetherall K; Mark PB
    J Am Soc Nephrol; 2020 Oct; 31(10):2434-2445. PubMed ID: 32817311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.